Literature DB >> 19731770

Prevalence of oropharyngeal colonization by Haemophilus influenzae type b in Iranian children.

A Karimi1, A Alborzi, A Fahimzad, M Gooya, A Esteghamati, S H Armin, F Fallah.   

Abstract

Healthy carriers of Haemophilus influenzae type b (Hib) play an important role in the spread of invasive disease. The aim of this study was to assess the need for Hib vaccination in Iranian children by estimating the prevalence of Hib oropharyngeal colonization among children in Tehran. Cultures were prepared from oropharyngeal swabs of 1000 children in 25 day-care centres in Tehran from October 2005 to March 2006. The prevalence of Hib carriers was 7.6%, similar to other developing countries prior to inoculation with the conjugate Hib vaccine. We recommend Hib vaccination be included in the Iranian national programme of immunization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731770

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  3 in total

1.  Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran.

Authors:  Fatemeh Teimouri; Abbas Kebriaeezadeh; Seyed Mohsen Zahraei; MohammadMahdi Gheiratian; Shekoufeh Nikfar
Journal:  Daru       Date:  2017-01-14       Impact factor: 3.117

2.  Effect of Haemophilus influenzae Type b Vaccination on Nasopharyngeal Carriage Rate in Children, Tehran, 2019.

Authors:  Sedigheh Rafiei Tabatabaei; Sara Mohammadzadeh; Seyed Mohsen Zahraei; Sussan Mahmoudi; Ghazaleh Ghandchi; Seyedeh Mahsan Hoseini-Alfatemi; Abdollah Karimi; Ahmadreza Shamshiri
Journal:  Biomed Res Int       Date:  2021-03-15       Impact factor: 3.411

3.  Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study.

Authors:  Amir Hashemi Meshkini; Abbas Kebriaeezadeh; Rasoul Dinarvand; Shekoufeh Nikfar; Mohammadgafar Habibzadeh; Iman Vazirian
Journal:  Daru       Date:  2012-08-30       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.